在择期进行经皮冠脉腔内成形术(PTCA)的462例患者中,89例辅以尿激酶治疗,26％为不稳定型心绞痛,34％为冠脉内血栓形成,27％为冠脉的内膜夹层分离,10％为冠脉急性闭塞,3％为大隐静脉移植支栓塞。有80例患者在冠脉急性闭塞前应用尿激酶治疗(A组);而167例类似患者不用尿激酶治疗,作为对照(B组)。两组手术成功率相似。严重心脏事件(冠脉急性闭塞、心肌梗塞、紧急冠脉搭桥术或死亡)在A组和B组的发 Among the 462 patients who underwent PTCA, 89 were treated with urokinase, 26% were unstable angina, 34% were intra-coronary thrombosis, and 27% were coronary Of the endocardial dissection, 10% of acute coronary occlusion, 3% of the great saphenous vein graft embolism. Eighty patients were treated with urokinase prior to acute coronary occlusion (group A); 167 patients without urokinase were used as controls (group B). The success rate of surgery was similar between the two groups. Serious cardiac events (acute coronary occlusion, myocardial infarction, emergency coronary bypass or death) occurred in groups A and B